Navigating 2025 Drug Pricing Policies webinar, panelists discussed the Most Favored Nation executive order, bills aimed at ...

Food and Drug Administration Commissioner Marty Makary said his agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other ...

There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

The strategies that the industry’s lobbyists use, or don’t deploy, matter as the Trump administration moves more decisively ...

Created to combat a lack of transparency in health care pricing, the All Payers Claims Database first launched in August, with average prices for medical procedures and reported prices for ...

The goal is to make drug prices more in line with European ones. If this were the case, it could result in a massive 24% hit on all firms’ US drug revenue, detrimental to Pfizer.

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability.

Successful trial data in a subset of hemophilia patients has set up Pfizer’s Hympavzi, which was approved eight months ago, for a label expansion ...

Policymakers will need to address the true drivers of high drug prices here at home, while simultaneously pressing our allies to contribute more abroad, writes PhRMA’s Steve Ubl.

Dive into how Donald Trump’s policies on drug pricing may cause European medicine costs to rise, impacting healthcare budgets across the region.